Product nameAnti-FLAP antibody
See all FLAP primary antibodies
DescriptionRabbit polyclonal to FLAP
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rabbit, Horse, Cow, Macaque monkey
- This antibody gave a positive signal in Human small intestine tissue lysate as well as the following whole cell lysates: U937; THP1.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab85227 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 14 kDa (predicted molecular weight: 14 kDa).|
|ICC/IF||Use a concentration of 5 µg/ml.|
FunctionRequired for leukotriene biosynthesis by ALOX5 (5-lipoxygenase). Anchors ALOX5 to the membrane. Binds arachidonic acid, and could play an essential role in the transfer of arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes.
Involvement in diseaseGenetic variations in ALOX5AP may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.
Note=Genetic variations in ALOX5AP may be associated with susceptibility to myocardial infarction. Involvement in myocardial infarction is however unclear: according to some authors (PubMed:14770184), a 4-SNP haplotype in ALOX5AP confers risk of myocardial infarction, while according to other (PubMed:17304054) ALOX5AP is not implicated in this condition.
Sequence similaritiesBelongs to the MAPEG family.
DomainThe C-terminal part after residue 140 is mostly unstructured.
Cellular localizationNucleus membrane. Endoplasmic reticulum membrane.
- Information by UniProt
- 5-lipoxygenase activating protein antibody
- AL5AP_HUMAN antibody
- ALOX 5AP antibody
All lanes : Anti-FLAP antibody (ab85227) at 1 µg/ml
Lane 1 : U937 (Human leukemic monocyte lymphoma cell line) Whole Cell Lysate
Lane 2 : THP1 (Human acute monocytic leukemia cell line) Whole Cell Lysate
Lane 3 : Human small intestine tissue lysate - total protein (ab29276)
Lysates/proteins at 10 µg per lane.
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 14 kDa
Observed band size: 14 kDa
Additional bands at: 175 kDa, 75 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 20 minutes
ICC/IF image of ab85227 stained MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab85227, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899 Dylight 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
This product has been referenced in:
- Werz O et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun 9:59 (2018). WB, IF ; Human . Read more (PubMed: 29302056) »
- Garscha U et al. Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase. Sci Rep 7:9398 (2017). ICC/IF . Read more (PubMed: 28839250) »